Eris Lifesciences was up 1.48% to Rs 519.90 at 10:01 IST on the BSE after the company said its board will consider share buyback on 3 July 2019.
The announcement was made after market hours yesterday, 24 June 2019.
Meanwhile, the S&P BSE Sensex was down by 3.98 points, or 0.01% to 39,118.98.
On the BSE, 4765 shares were traded in the counter so far compared with average daily volumes of 596 shares in the past two weeks. The stock had hit a high of Rs 539 and a low of Rs 516.95 so far during the day. It hit a 52-week high of Rs 798.80 on 27 August 2018 and a 52-week low of Rs 475 on 19 June 2019.
On a consolidated basis, Eris Lifesciences' net profit fell 3.9% to Rs 53.88 crore on a 1.5% rise in the net sales to Rs 211.09 crore in Q4 March 2019 over Q4 March 2018.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.